Mirum Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Mirum Pharmaceuticals, Inc. (MIRM) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$24.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-25
- Mirum Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$24.88M.
- Mirum Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$89.94M.
- Mirum Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$164.95M.
- Mirum Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$142.66M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 8 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|
| 2025-12-31 | -$24.88M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$89.94M 10-K · filed 2026-02-25 | |
| 2023-12-31 | -$164.95M 10-K · filed 2026-02-25 | |
| 2022-12-31 | -$142.66M 10-K · filed 2025-02-26 | |
| 2021-12-31 | -$84.22M 10-K · filed 2024-03-15 | |
| 2020-12-31 | -$103.37M 10-K · filed 2022-03-09 | |
| 2019-12-31 | -$52.65M 10-K · filed 2021-03-09 | |
| 2018-12-31 | -$17.35M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |